{
    "nct_id": "NCT03194867",
    "official_title": "A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma",
    "inclusion_criteria": "Inclusion criteria:\n\n* Patients must have a known diagnosis of multiple myeloma with evidence of measurable disease, as defined below:\n\n  * Serum M-protein ≥1 g/dL (≥0.5 g/dL in case of immunoglobulin A [IgA] disease), AND/OR\n  * Urine M-protein ≥200 mg/24 hours, OR\n  * In the absence of measurable M-protein, serum immunoglobulin free light chain ≥10 mg/dL, and abnormal serum immunoglobulin kappa lambda free light chain ratio (<0.26 or >1.65).\n* Patients must have received prior treatment with an immunomodulatory drug (IMiD) (for ≥2 cycles or ≥2 months of treatment) and a proteasome inhibitor (PI) (for ≥2 cycles or ≥2 months of treatment).\n* Patients must have received at least 3 prior lines of therapy (Note: Induction therapy and stem cell transplant ± maintenance will be considered as one line).\n* Patient must have achieved MR or better with any anti-myeloma therapy (ie, primary refractory disease is not eligible).\n\nExclusion criteria:\n\n* Prior exposure to isatuximab or participated clinical studies with isatuximab.\n* Prior exposure to any agent (approved or investigational) that blocks the programmed cell death-1 (PD-1)/PD-L1 pathway.\n* Evidence of other immune related disease/conditions.\n* History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.\n* Has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted.\n* Has allogenic haemopoietic stem cell (HSC) transplant.\n* Prior treatment with idelalisib (a PI3K inhibitor).\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) >2.\n* Poor bone marrow reserve.\n* Poor organ function.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}